Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIT allergoid vaccine trial for grass and cupressaceae allergy
2024-514524-16-00Phase 3Authorised
- Sponsor
- Inmunotek
- Start
- May 2021
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MG01 + T521 in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and allergic asthma (2 arms), sponsored by Inmunotek. Primary endpoint: Combined symptom and medication score in rhinitis/rhinoconjunctivitis. Planned start May 2021; status: authorised.
02
Drugs
MG01 + T521
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2024-514524-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514524-16-00.